These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30721246)

  • 41. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
    Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
    J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.
    Sabarimurugan S; Madurantakam Royam M; Das A; Das S; K M G; Jayaraj R
    Mol Diagn Ther; 2018 Dec; 22(6):653-669. PubMed ID: 30259393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revisiting determinants of prognosis in cutaneous melanoma.
    Weiss SA; Hanniford D; Hernando E; Osman I
    Cancer; 2015 Dec; 121(23):4108-23. PubMed ID: 26308244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis.
    Polini B; Carpi S; Romanini A; Breschi MC; Nieri P; Podestà A
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):486-499. PubMed ID: 30481404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
    Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
    Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects.
    Blokx WA; van Dijk MC; Ruiter DJ
    Histopathology; 2010 Jan; 56(1):121-32. PubMed ID: 20055910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Wandler A; Riber-Hansen R; Hager H; Hamilton-Dutoit SJ; Schmidt H; Nielsen BS; Stougaard M; Steiniche T
    Melanoma Res; 2017 Oct; 27(5):417-428. PubMed ID: 28614272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomarkers for melanoma.
    Torabian S; Kashani-Sabet M
    Curr Opin Oncol; 2005 Mar; 17(2):167-71. PubMed ID: 15725923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
    Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
    J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles.
    Shiiyama R; Fukushima S; Jinnin M; Yamashita J; Miyashita A; Nakahara S; Kogi A; Aoi J; Masuguchi S; Inoue Y; Ihn H
    Melanoma Res; 2013 Oct; 23(5):366-72. PubMed ID: 23863473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma.
    Wang LX; Wan C; Dong ZB; Wang BH; Liu HY; Li Y
    Med Sci Monit; 2019 Apr; 25():2896-2907. PubMed ID: 31004080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells.
    Ulmer A; Schmidt-Kittler O; Fischer J; Ellwanger U; Rassner G; Riethmüller G; Fierlbeck G; Klein CA
    Clin Cancer Res; 2004 Jan; 10(2):531-7. PubMed ID: 14760074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation.
    Wei C; Lu N; Wang L; Zhang Y; Feng Z; Yang Y; Qi F; Gu J
    Oncol Rep; 2018 Jun; 39(6):2553-2562. PubMed ID: 29620240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    Jayawardana K; Schramm SJ; Tembe V; Mueller S; Thompson JF; Scolyer RA; Mann GJ; Yang J
    J Invest Dermatol; 2016 Jan; 136(1):245-254. PubMed ID: 26763444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma.
    Dunkel Y; Reid AL; Ear J; Aznar N; Millward M; Gray E; Pearce R; Ziman M; Ghosh P
    Sci Rep; 2018 Dec; 8(1):18036. PubMed ID: 30575751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Golgi-Related Proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in Cutaneous Melanoma: Patterns of Expression and Prognostic Significance.
    Donizy P; Kaczorowski M; Biecek P; Halon A; Szkudlarek T; Matkowski R
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.
    Sykes EK; McDonald CE; Ghazanfar S; Mactier S; Thompson JF; Scolyer RA; Yang JY; Mann GJ; Christopherson RI
    Proteomics Clin Appl; 2018 May; 12(3):e1700094. PubMed ID: 29227041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA regulation of melanoma progression.
    Bonazzi VF; Stark MS; Hayward NK
    Melanoma Res; 2012 Apr; 22(2):101-13. PubMed ID: 22209751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.